In a metabolic syndrome model, the GLP-1 receptor agonist exendin-4 was given to hyperglycemia mice, resulting in sustained plasma glucose reduction, weight loss, and enhances insulin sensitivity over multiple weeks of treatment (Young et al., 1999). This evidence concerns the gene GLP1R and metabolic syndrome.